Melanoma transection doesn't affect overall survival

September 18, 2012
Melanoma transection doesn't affect overall survival
Melanoma transection does not affect disease-free survival or mortality, according to a study published online Sept. 10 in the Journal of the American Academy of Dermatology.

(HealthDay)—Melanoma transection does not affect disease-free survival or mortality, according to a study published online Sept. 10 in the Journal of the American Academy of Dermatology.

Mohsin Mir, M.D., from the Baylor College of Medicine in Houston, and colleagues retrospectively reviewed cases of melanoma at Baylor from 2000 to 2008. Transection rates were determined in 479 cases, and transected tumors were matched with non-transected cases to evaluate survival in a case-control manner.

The researchers found that the rate of melanoma transection was 1.5 percent for excisional biopsies, 4.1 percent for punch biopsies, and 9.0 percent for saucerization biopsies. Mean disease-free survival was 911 days for controls and 832.7 days for the transected group (P = 0.67). Overall survival was not significantly different between the groups (1,073.7 days for control group versus 1,012.4 days for transected group).

"Punch and saucerization biopsies were more likely to transect tumors than excisional biopsies," the authors write. "The transection of did not affect overall disease-free survival or mortality in the population studied."

Explore further: Shave biopsy is a safe and acceptable method for initial evaluation of melanoma

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Shave biopsy is a safe and acceptable method for initial evaluation of melanoma

May 23, 2011
A shave biopsy is a reasonably safe and accurate method for the initial diagnosis of melanoma, according to a study published in the April issue of the Journal of the American College of Surgeons. In the past, some physicians ...

Researchers study childhood melanoma characteristics

September 7, 2012
Melanoma, newly diagnosed in more than 76,000 Americans in 2011, is the most common and dangerous form of skin cancer. Melanoma is rare in children, accounting for 1 to 4 percent of all melanoma cases and just 3 percent of ...

ASCO: Trametinib improves survival in metastatic melanoma

June 5, 2012
(HealthDay) -- For patients with metastatic melanoma with activating mutations in serine-threonine protein kinase B-RAF (BRAF), treatment with the oral selective MEK inhibitor trametinib is associated with improved progression-free ...

Women have clear melanoma survival advantage over men

May 1, 2012
(HealthDay) -- Women with localized melanoma have a consistent advantage over men of approximately 30 percent for survival and progression, according to a study published online April 30 in the Journal of Clinical Oncology.

Tumor-Infiltrating lymphocyte grade IDs melanoma survival

June 20, 2012
(HealthDay) -- Tumor-infiltrating lymphocyte (TIL) grade is an independent predictor of melanoma-specific survival and sentinel lymph node (SLN) status in patients with localized primary cutaneous melanoma, according to a ...

Invasive melanoma may be more likely in children than adults

October 5, 2011
A Johns Hopkins Children's Center study of young people with melanoma, a deadly form of skin cancer, has found that some children have a higher risk of invasive disease than adults.

Recommended for you

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

Liquid biopsy results differed substantially between two providers

December 14, 2017
Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. Liquid biopsy is a new and noninvasive alternative ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

gwrede
not rated yet Sep 19, 2012
And what exactly is "transection"?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.